Synthesis and biological properties of new chimeric galanin analogue GAL(1-13)-[Ala10,11]ET-1(6-21)-NH2

Journal of Physiology and Pharmacology

Volumn 56, Issue 2, 2005, Pages 273-285

  Ruczyński, Jarosław ^a   Konstanski Z ^b   Cybal, M ^b   Petrusewicz, J ^b   Wojcikowski C ^b   Rekowski, P ^a   Kaminska B ^b  

^a UNIVERSITY OF GDA SK   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Chimeric analogues; Galanin; Gastric smooth muscles contraction; Insulin secretion

Indexed keywords

ENDOTHELIN 1; GALANIN; GALANIN DERIVATIVE; GALANIN RECEPTOR; GALANIN RECEPTOR ANTAGONIST; GALANIN[1-13][10,11 ALANINE] ENDOTHELIN 1 [6-21] AMIDE; GALANIN[1-15]; GLUCOSE; INSULIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CHIMERA; GASTROINTESTINAL TRACT EXAMINATION; HORMONE RECEPTOR INTERACTION; INSULIN RELEASE; MALE; NONHUMAN; PEPTIDE SYNTHESIS; RAT; SMOOTH MUSCLE CONTRACTION; STOMACH MUSCLE; SYNTHESIS;

AMINO ACID SEQUENCE; ANIMALS; GALANIN; INSULIN; MALE; MOLECULAR SEQUENCE DATA; MUSCLE CONTRACTION; MUSCLE, SMOOTH; RATS; RATS, WISTAR; RECEPTORS, GALANIN; RECOMBINANT FUSION PROTEINS; STOMACH;

EID: 21344454462     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Tatemoto K, Rökaeus A, Jörnvall H, McDonald TJ, Mutt V. Galanin - a novel biologically active peptide from porcine intestine. FEBS Lett 1983; 164: 124-128.
2. Vrontakis MA. Galanin: a biologically active peptide. Curr Drug Targets CNS Neural Disord 2002; 1: 531-541.
3. Branchek TA, Smith KE, Gerald C, Walker M. Galanin receptor subtypes. Trends Pharm Sci 2000; 21: 109-116.
4. Ruczyński J, Rekowski P. Biological action of galanin and its significance in physiologic and pathologic processes. Postȩpy Biochemii 2002; 48: 306-316.
5. Crawley JN. The role of galanin in feeding behaviour. Neuropeptides 1999; 33: 369-375.
6. Counts SE, Perez SE, Ginsberg SD, De Lacalle S, Mufson EJ. Galanin in Alzheimer disease. Mol Interv 2003; 3: 137-156.
7. Ögren SO, Schött PA, Kehr J, Misane I, Razani H. Galanin and learning. Brain Res 1999; 848: 174-182.
8. Kageyama H, Takenoya F, Kita T, Hori T, Guan JL, Shioda S. Galanin-like peptide in the brain: effects on feeding, energy metabolism and reproduction. Regul Pept 2005; 126: 21-26.
9. Ciosek J, Cisowska A. Centrally administered galanin modifies vasopressin and oxytocin release from the hypothalamo-neurohypophysial system of euhydrated and dehydrated rats. J Physiol Pharmacol 2003; 54: 625-641.
10. Ciosek J, Cisowska A, Da̧browski R. Galanin affects vasopressin and oxytocin release from the hypothalamo-neurohypophysial system in haemorrhaged rats. J Physiol Pharmacol 2003; 54: 233-246.
11. 2 and its new analogues on glucose-induced insulin secretion. Pol J Pharmacol 2002; 54: 133-141.
12. Kuwahara A, Ozaki T, Yanaihara N. Galanin suppresses neurally evoked contractions of circular muscle in the guinea-pig ileum. Eur J Pharmacol 1989; 164: 175-178.
13. Tamura K, Palmer JM, Wood JD. Galanin suppresses nicotinic synaptic transmission in the myenteric plexus of guinea-pig small intestine. Eur J Pharmacol 1987; 136: 445-446.
14. Ekblad E, Hakanson R, Sundler F, Wahlstedt C. Galanin: neuromodulatory and direct contractile effects on smooth muscle preparations. Brit J Pharmacol 1985; 86: 241-246.
15. Fox JET, McDonald TJ, Kostolanska F, Tatemoto K. Galanin: an inhibitory neural peptide of the canine small intestine. Life Sci 1986; 39: 103-110.
16. 2+ for galanin-induced contractions of rat gastric fundus, jejunum and colon. J Physiol Pharmacol 2000; 51: 821-831.
17. Crawley JN. Biological actions of galanin. Regul Peptides 1995; 59: 1-16.
18. Bartfai T, Fisone G, Langel Ü. Galanin and galanin antagonists: molecular and biochemical perspectives. Trends Pharmacol Sci 1992; 13: 312-317.
19. Bartfai T, Langel Ü. Galanin receptor ligands as potential therapeutic agents in depression and neurodegeneration. Eur J Med Chem 1995; 30: 163S-174S.
20. Bedecs K, Berthold M, Bartfai T. Galanin - 10 years with a neuroendocrine peptide. Int J Biochem Cell Biol 1997; 27: 337-349.
21. Kask K, Langel Ü, Bartfai T. Galanin - a neuropeptide with inhibitory actions. Cell Mol Neurobiol 1995; 15: 653-673.
22. Florén A, Land T, Langel Ü. Galanin receptor subtypes and ligand binding. Neuropeptides 2000; 34: 331-337
23. Bartfai T, Bedecs K, Land T, Langel Ü, Bertorelli R, Girotti P, Consolo S, Xu X, Wiesenfeld-Hallin Z, Nilsson S, Pieribone VA, Hökfelt T. M-15: high-affinity chimeric peptide that blocks the neuronal actions of galanin in the hippocampus, locus coeruleus, and spinal cord. Proc Natl Acad Sci USA 1991; 88: 10961-10965.
24. Gregersen S, Lindskog S, Land T, Langel Ü, Bartfai T, Ahrér B. Blockade of galanin-induced inhibition of insulin secretion from isolated mouse islets by the non-methionine containing antagonist M35. Eur J Pharmacol 1993; 232: 35-39.
25. Gu ZF, Rossowski WJ, Coy DH, Pradhan TK, Jensen RT. Chimeric galanin analogs that function as antagonists in the CNS are full agonists in gastrointestinal smooth muscle. J Pharmacol Exp Ther 1993; 266: 912-918.
26. 8]galanin(1-15)ol is a potent galanin antagonist on insulin release. Biomed Res 1997; 18: 49-56.
27. Langel Ü, Bartfai T. Chemistry and molecular biology of galanin receptor ligands. Ann NY Acad Sci 1998; 863: 86-93.
28. Langel Ü, Land T, Bartfai T. Design of chimeric peptide ligands to galanin receptors and substance P receptors. Int J Pept Protein Res 1992; 39: 516-522.
29. Lindskog S, Ahrén B, Land T, Langel Ü, Bartfai T. The novel high-affinity antagonist, galantide, blocks the galanin-mediated inhibition of glucose-induced insulin secretion. Eur J Pharmacol 1992; 210: 183-188.
30. Langel Ü, Pooga M, Kairane C, Zilmer M, Bartfai T. A galanin-mastoparan chimeric peptide activates the Na+,K(+)-ATPase and reverses its inhibition by ouabain. Regul Pept 1996; 62: 47-52.
31. Östenson CG, Zaitsev S, Berggren PO, Efendic S, Langel Ü, Bartfai T. Galparan: a powerful insulin-releasing chimeric peptide acting at a novel site. Endocrinology 1997; 138: 3308-3313.
32. Pooga M, Juréus A, Rezael K, Hasanvan H, Saar K, Kask K, Kjellén P, Land T, Halonen J, Mäeorg U, Uri A, Solyom S, Bartfai T, Langel Ü. Novel galanin receptor ligands. J Peptide Res 1998; 51: 65-74.
33. Wiesenfeld-Hallin Z, Xu XJ, Langel Ü, Bedecs K, Hökfelt T, Bartfai T. Galanin-mediated control of pain: enhanced role after nerve injury. Proc Natl Acad Sci USA 1992; 89: 3334-3337.
34. Chan WC, White PD. Fmoc Solid Phase Peptide Synthesis. A Practical Approach. Oxford, Oxford University Press, 2000.
35. Vane JR. A sensitive method for assay of 5 hydroxitryptamine. Br J Pharmacol 1957; 12: 344-349.
36. Lacy PE, Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 1967; 16: 35-39.
37. Morgan CR, Lazarow A. Immunoassay of insulin: two antibody system. Plasma insulin levels of normal, subdiabetic and diabetic rats. Diabetes 1963; 12: 115-120.
38. Juréus A, Langel Ü, Bartfai T. L-Ala-substituted rat galanin analogs distinguish between hypothalamic and jejunal galanin receptor subtypes. J Peptide Res 1997; 49: 195-200.
39. Kask K, Berthold M, Bourne J, Andell S, Langel Ü, Bartfai T. Binding and agonist/antagonist actions of M35, galanin(1-13)-bradykinin(2-9)amide chimeric peptide in Rin m5F insulinoma cells. Regul Peptides 1995; 59: 341-348.
40. Land T, Langel Ü, Löw M, Berthold M, Undén A, Bartfai T. Linear and cyclic N-terminal galanin fragments and analogs as ligands at the hypothalamic galanin receptor. Int J Peptide Prot Res 1991; 38: 267-272.
41. Rekowski P, Borowiec A, Drużyńska J, Kusiak E. New chimeric analogues of galanin: synthesis and effects on the glucose-induced insulin secretion. LIPS 1998; 5: 417-420.
42. Śliwiński W, Korolkiewicz RP, Rekowski P, Halama A, Korolkiewicz KZ. Actions of galanin and some of its analogues on rat isolated gastric fundus. Fundam Clin Pharmacol 1996; 10: 442-449.
43. 8]scyliorhinin-I in rat isolated fundus strips. Med Sci Monit 2002; 8: BR19-BR23.